Kenna Mills Shaw, Executive Director, Institute for Personalized Cancer Therapy at MD Anderson Cancer Center, shared a post about a paper she co-authored with colleagues on LinkedIn:
“Excited to see this important framework see the light of day in hopes that other programs come forward to continue to push us to add novel biomarkers beyond mutations so we can adapt approaches and tumors evolve.
Proud to share our Cancer Cell commentary on ASCEND-CRC-an adaptive platform trial rethinking how we treat and track mCRC.”
Title: Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC program
Authors: Salvador Alonso, Kanwal Raghav, Van K. Morris, Kristin Alfaro-Munoz, Tanios Bekaii-Saab, Timothy L. Cannon, Ryan B. Corcoran, Nicholas Duesbery, Manju George, David Hsu, Christopher Lieu, Anirban Maitra, Dipen Maru, Jasmine A. McQuerry, David Menter, Jonathan Mizrahi, Kimmie Ng, Aparna Parikh, Kunal Rai, Michelle C. Sangar, Kenna R. Shaw, John Paul Shen, John H. Strickler, Ann D. Feehan, Alda L. Tam, Guglielmo Vetere, Rona Yaeger, Ying Yuan, Xiling Shen, Andrea H. Bild, Scott Kopetz
More posts about colorectal cancer on OncoDaily.